$462.60-6.61 (-1.41%)
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. in the Healthcare sector is trading at $462.60. The stock is currently 28% below its 52-week high of $643.99, remaining 12.1% below its 200-day moving average. Technical signals show oversold RSI of 25 and bearish MACD signal, explaining why TMO maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four se...
Today we're going to take a look at the well-established Thermo Fisher Scientific Inc. ( NYSE:TMO ). The company's...
Hedge fund billionaire Daniel Loeb assumed a stake in the Life Sciences Tools & Services company Thermo Fisher Scientific Inc at Third Point LLC in the fourth quarter of FY25. As of Dec. 31, 2025, Loeb bought 50,000 shares in the company. Recent Key Events In February, Thermo Fisher Scientific’s Board approved a quarterly dividend of $0.47 per share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. The new dividend represents a 10% increase from the prior $0.43 payout.
Thermo Fisher Scientific recently opened its flagship U.S. Bioprocess Design Center at its Plainville, Massachusetts site, expanding by 4,000 square feet to offer end-to-end bioproduction workflow support for biologics, vaccines, and cell and gene therapies alongside hands-on customer training. This new center integrates Thermo Fisher’s bioprocess expertise with its existing 290,000-square-foot sterile fill-finish and viral vector facility, reinforcing its role as a comprehensive partner...
Corning (GLW) reported Q1 2026 core sales of $4.35 billion, representing an 18% year-over-year increase. The core insight hiding beneath this headline beat is how entirely the AI-driven acceleration is offsetting the more modest growth currently seen in the company's traditional Glass Innovations segment.
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]